{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:28:42Z","timestamp":1774528122913,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction:<\/jats:title>\n            <jats:p>Malignant catatonia (MC) is a movement disorder syndrome characterized by immobility, rigidity, and consciousness disorders that develops in association with mental and physical diseases. It is often fatal due to hyperthermia, rhabdomyolysis, and acute kidney injury. Its clinical symptoms are similar to those of another disorder, neuroleptic malignant syndrome (NMS), and it is often difficult to distinguish between the 2 disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>An Asian woman in her 60s with history of schizophrenia. She was admitted to our hospital because of symptoms such as fever, unconsciousness, and muscle rigidity. Blood tests showed kidney injury and high creatinine kinase levels.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>At the time of admission, she had been diagnosed with NMS complicated by pulmonary aspergillosis and was undergoing treatment although there was no improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Subsequently, the administration of propofol, a gamma-aminobutyric acid A agonist, markedly improved the symptoms, and the diagnosis was corrected to MC. At the beginning of her hospitalization, she received dantrolene, bromocriptine, amantadine, and L-3,4-dihydroxyphenylalanine as treatment for NMS, but her symptoms did not improve. With propofol, which is used for sedation, her catatonic symptoms improved markedly. Quetiapine administration further improved the symptoms, and it eventually resolved completely.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient's MC was in remission. Prolonged intensive care management resulted in a decline in activities of daily living, and she required rehabilitation at another hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This is the first report of MC with suspected involvement of pulmonary aspergillosis. MC differs from NMS, in that it is treated more effectively with gamma-aminobutyric acid A agonists. Although benzodiazepines are the first choice for the diagnosis and treatment of MC, they are ineffective for majority of patients with schizophrenia. However, even in such cases, propofol and quetiapine are effective, and they facilitate diagnosis and treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025967","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:58:32Z","timestamp":1620763112000},"page":"e25967","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Successful diagnosis and treatment of pulmonary aspergillosis-related malignant catatonia using propofol and quetiapine"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8532-0166","authenticated-orcid":false,"given":"Kazuhito","family":"Nomura","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Sapporo Medical University Hospital, Sapporo-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonoko","family":"Sakawaki","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Hakodate Municipal Hospital, Hakodate-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Sakawaki","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Hakodate Municipal Hospital, Hakodate-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Yamaoka","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sunagawa City Medical Center, Sunagawa-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wakiko","family":"Aisaka","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Sapporo Medical University Hospital, Sapporo-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Teine Keijinkai Hospital, Sapporo-shi, Hokkaido, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Takeyama","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Hakodate Municipal Hospital, Hakodate-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Sapporo Medical University Hospital, Sapporo-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eichi","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Sapporo Medical University Hospital, Sapporo-shi"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"R1-20250504","article-title":"NMS, and why we should call it (malignant) catatonia","volume":"20","author":"Johnson","year":"2006","journal-title":"J J P"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e1752","DOI":"10.1097\/MD.0000000000001752","article-title":"A case report of catatonia and neuroleptic malignant syndrome with multiple treatment modalities: short communication and literature review","volume":"94","author":"Chiou","year":"2015","journal-title":"Medicine"},{"key":"R3-20250504","first-page":"378","article-title":"Specific treatment of the neuroleptic malignant syndrome","volume":"44","author":"Caroff","year":"1998","journal-title":"Biol Psychiatry"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1176\/ajp.142.10.1137","article-title":"Neuroleptic malignant syndrome","volume":"142","author":"Levenson","year":"1985","journal-title":"Am J Psychiatry"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0447.1996.tb09814.x","article-title":"Catatonia. I. Rating scale and standardized examination","volume":"93","author":"Bush","year":"1996","journal-title":"Acta Psychiatr Scand"},{"key":"R6-20250504","first-page":"385","article-title":"Acute life-threatening catatonia","volume":"53","author":"H\u00e4fner","year":"1982","journal-title":"Nervenarzt"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/jnp.6.1.1","article-title":"Malignant catatonia","volume":"6","author":"Philbrick","year":"1994","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2215-0366(19)30190-7","article-title":"Catatonia and the immune system: a review","volume":"6","author":"Rogers","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) consensus group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1080\/13693780600904918","article-title":"Issues with galactomannan testing","volume":"44","author":"Verweij","year":"2006","journal-title":"Med Mycol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1309\/LM8BW8QNV7NZBROG","article-title":"(1-3)-\u03b2-D-glucan assay: a review of its laboratory and clinical application","volume":"42","author":"Wright","year":"2011","journal-title":"Lab Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1093\/cid\/ciy859","article-title":"Voriconazole resistance and mortality in invasive aspergillosis: a multicenter retrospective cohort study","volume":"68","author":"Lestrade","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/00365540410020406","article-title":"A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan","volume":"36","author":"Kohno","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R15-20250504","first-page":"34","article-title":"Prevalence and risk factors for development of delirium in surgical and trauma ICU patients","volume":"65","author":"Pandharipande","year":"2008","journal-title":"J Trauma"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1001\/jama.298.22.2644","article-title":"Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial","volume":"298","author":"Pandharipande","year":"2007","journal-title":"JAMA"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2169\/internalmedicine.55.6613","article-title":"Catatonic symptoms appearing before autonomic symptoms help distinguish neuroleptic malignant syndrome from malignant catatonia","volume":"55","author":"Komatsu","year":"2016","journal-title":"Intern Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/2045125316681750","article-title":"Clonazepam improves dopamine supersensitivity in a schizophrenia patient: a case report","volume":"7","author":"Fukai","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"R19-20250504","first-page":"141","article-title":"Pharmacotherapy","author":"Rosebush","year":"2004","journal-title":"Catatonia: From Psychopathology to Neurobiology"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S147897","article-title":"Systematic review of catatonia treatment","volume":"14","author":"Pelzer","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.psym.2012.03.003","article-title":"Lysis of catatonic withdrawal by propofol in a bone-marrow transplant recipient with adenovirus limbic encephalitis","volume":"54","author":"Alfson","year":"2013","journal-title":"Psychosomatics"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12888-019-2107-6","article-title":"First known case of catatonia due to cyclosporine A-related neurotoxicity in a pediatric patient with steroid-resistant nephrotic syndrome","volume":"19","author":"Heekin","year":"2019","journal-title":"BMC Psychiatry"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/j.1476-5381.1995.tb16660.x","article-title":"Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones","volume":"116","author":"Orser","year":"1995","journal-title":"Br J Pharmacol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"e6566","DOI":"10.1097\/MD.0000000000006566","article-title":"Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: a case report","volume":"96","author":"Ohi","year":"2017","journal-title":"Medicine"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/NDT.S52311","article-title":"Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor?. A case series of 39 patients","volume":"9","author":"Yoshimura","year":"2013","journal-title":"Neuropsychiatr Dis Treat"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:41:56Z","timestamp":1746337316000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025967"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":25,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025967","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"2020-12-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}